Literature DB >> 4066782

Xeroderma pigmentosum D-HeLa hybrids with low and high ultraviolet sensitivity associated with normal and diminished DNA repair ability, respectively.

R T Johnson, S Squires, G C Elliott, G L Koch, A J Rainbow.   

Abstract

Fusion between HeLa and fibroblasts from complementation group D xeroderma pigmentosum (XPD) followed by challenge with small doses of ultraviolet light (u.v.) results in the production of hybrid cells expressing either HeLa (HD1) or XPD-like (HD2) sensitivity to u.v. and related repair capacity. Assays used included unscheduled DNA synthesis (UDS), DNA break accumulation in the presence of inhibitors of DNA repair synthesis and host cell reactivation of irradiated adenovirus. Complementation assay in heterokaryons reveals limited ability of HD2 to restore UDS in XPD nuclei. We believe this complementation is more apparent than real since proliferating hybrids of HD2 and XPD parentage are without exception u.v.-sensitive and express limited excision repair. On the other hand hybrids between HD2 and XPC, XPE or XPF fibroblasts show true complementation resulting in a return to normal u.v. sensitivity and elevated repair ability.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4066782     DOI: 10.1242/jcs.76.1.115

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  13 in total

1.  Phosphorylation of XPB helicase regulates TFIIH nucleotide excision repair activity.

Authors:  Frédéric Coin; Jérome Auriol; Angel Tapias; Pascale Clivio; Wim Vermeulen; Jean-Marc Egly
Journal:  EMBO J       Date:  2004-11-18       Impact factor: 11.598

2.  Molecular cloning and characterization of a mammalian excision repair gene that partially restores UV resistance to xeroderma pigmentosum complementation group D cells.

Authors:  J E Arrand; N M Bone; R T Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Lack of complementation between xeroderma pigmentosum complementation groups D and H.

Authors:  R T Johnson; G C Elliott; S Squires; V C Joysey
Journal:  Hum Genet       Date:  1989-02       Impact factor: 4.132

4.  Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK.

Authors:  S J Araújo; F Tirode; F Coin; H Pospiech; J E Syväoja; M Stucki; U Hübscher; J M Egly; R D Wood
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

5.  The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process.

Authors:  Pierre Chymkowitch; Nicolas Le May; Pierre Charneau; Emmanuel Compe; Jean-Marc Egly
Journal:  EMBO J       Date:  2010-12-14       Impact factor: 11.598

6.  Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations.

Authors:  Emmanuel Compe; Pascal Drané; Camille Laurent; Karin Diderich; Cathy Braun; Jan H J Hoeijmakers; Jean-Marc Egly
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

7.  Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH.

Authors:  F Coin; E Bergmann; A Tremeau-Bravard; J M Egly
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

8.  Defects in the DNA repair and transcription gene ERCC2(XPD) in trichothiodystrophy.

Authors:  K Takayama; E P Salazar; B C Broughton; A R Lehmann; A Sarasin; L H Thompson; C A Weber
Journal:  Am J Hum Genet       Date:  1996-02       Impact factor: 11.025

9.  Phosphorylation of steroidogenic factor 1 is mediated by cyclin-dependent kinase 7.

Authors:  Aurélia E Lewis; Marte Rusten; Erling A Hoivik; Elisabeth L Vikse; Magnus L Hansson; Annika E Wallberg; Marit Bakke
Journal:  Mol Endocrinol       Date:  2007-09-27

10.  Both XPD alleles contribute to the phenotype of compound heterozygote xeroderma pigmentosum patients.

Authors:  Takahiro Ueda; Emmanuel Compe; Philippe Catez; Kenneth H Kraemer; Jean-Marc Egly
Journal:  J Exp Med       Date:  2009-11-23       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.